Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Explore available award and grant opportunities for fellows-in-training.
Make a choice that matters
The best care starts with the best information. See videos to help answer your questions.
The ACR is accepting applications for mini curriculums, which are educational activities or curriculums to enhance the ACR Core Curriculum Outline.
TOCILIZUMAB (Actemra) is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin IgG1κ subclass. Two heavy chain and two light chain polypeptides are linked by intra- and inter-molecular disulfide bonds. Endogenous IL-6 is induced by inflammatory stimuli and mediates a variety of immunological responses. Inhibition of IL-6 receptors by tocilizumab leads to a reduction in cytokine and acute phase reactant production.
Patient Medication Guide
Full Prescribing Information
Tocilizumab is indicated for:
Rheumatoid Arthritis (RA)
Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Systemic Juvenile Arthritis
Most common adverse reactions (>5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT and injection site reactions.
If the answer is yes to any of these questions, notify the ordering provider before initiating the infusion therapy.
Updated February 2020 - ARP Practice Committee
DISCLAIMER:The information contained in this biologic reference guide is offered solely for purposes of providing health care professionals with a quick and initial reference. Before prescribing or administering any drug contained in this biologic reference guide, health professionals should read the manufacturer's complete prescribing information in order to be informed of the various clinical considerations to be taken into account. The American College of Rheumatology is providing this information as a benefit and service in furtherance of its educational mission. By providing this information, ACR is not endorsing or recommending any of the listed companies or any of their drugs or other products. The information contained in the biologic reference guides reflect the conclusions of the individual companies and not those of the ACR which specifically disclaims any responsibility or liability for the use of such information and/or for the performance of any of the drugs listed in this biologic reference guide.